Brief: Dermapharm Holding FY Unadjusted EBITDA Up By 2.8%
March 10 (Reuters) - Dermapharm Holding SE DMPG.DE: DERMAPHARM HOLDING SE - IN 2025, CONSOLIDATED REVENUE DECREASES TO EUR 1,165.0 MILLION (-1.3%) DERMAPHARM HOLDING SE - FY UNADJUSTED EBITDA RISES BY 2.8% TO EUR 317.6 MILLION Further company coverage: DMPG.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit